Basilea collects $37.5 million milestone tied to Cresemba sales
Basilea Pharmaceutica receives a $37.5 million milestone after Pfizer's European Cresemba sales, per GlobeNewswire. Worldwide sales rose 25%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Basilea Pharmaceutica (BSLN) said Pfizer's sales of Cresemba in Europe triggered a milestone payment of $37.5 million to the company, according to GlobeNewswire.
For the twelve months ended June 2026, worldwide in-market sales of the drug came to $817 million, a 25% gain from a year earlier.
The payment is linked to European sales, while the full-year figures cover the entire world market.
why it matters
For investors this is a routine commercial update on an established product. Payments tied to sales suggest Cresemba's revenue keeps growing, though how much these receipts add to Basilea's overall results has not been detailed.
tags
instruments
sources
- Basilea Pharmaceutica Ltd (BSLN) Receives $37.5M Cresemba Milestone Payment — globenewswire.com, 3 November 2026 at 06:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗